Study of Novel Autoantibodies in Schizophrenia

Ruth Whelan, David St Clair, Colette J. Mustard, Philomena Hallford, Jun Wei (Corresponding Author)

Research output: Contribution to journalArticle

7 Citations (Scopus)
3 Downloads (Pure)

Abstract

A recent genome-wide association (GWA) study confirmed 108 genetic loci that were strongly associated with schizophrenia. Fifteen schizophrenia-associated genes were selected for this study based on a number of selection criteria including their high expression in both brain tissues and B-lymphocyte cells. We aimed to investigate whether individuals with schizophrenia showed different levels of plasma IgG antibodies against protein-derived fragments encoded by these 15 genes. A total of 356 plasma samples were used to analyze circulating IgG antibodies against 18 target peptide antigens using an in-house enzyme-linked immunosorbent assay. Of 18 antigens tested, 6 (derived from DPYD, MAD1L1, ZNF804A, DRD2, TRANK1, and MMP16, respectively) showed increased IgG levels and 3 (derived from TSNARE1, TCF4, and VRK2, respectively) showed decreased IgG levels in patients with schizophrenia compared with control subjects. Receiver operating characteristic (ROC) curve analysis revealed that the anti-TRANK1 IgG assay had the area under the ROC curve of 0.68 (95% CI = 0.62-0.73), with the highest sensitivity of 20.7% against specificity of 95.2% among all 18 tests. There was no difference in positivity of anti-double strand DNA IgG between the patient group and the control group and no correlation between total IgG levels and each individual IgG level tested. Although risperidone treatment showed confounding effects on overall IgG levels in the circulation (combined P = .005), anti-TRANK1 IgG levels did not appear to be significantly affected (t = 1.358, P = .176). In conclusion, this study suggests that circulating anti-TRANK1 IgG is likely to serve as a biomarker for identification of a subgroup of schizophrenia.

Original languageEnglish
Pages (from-to)1341-1349
Number of pages9
JournalSchizophrenia Bulletin
Volume44
Issue number6
Early online date24 Jan 2018
DOIs
Publication statusPublished - 17 Oct 2018

Fingerprint

Autoantibodies
Schizophrenia
Immunoglobulin G
ROC Curve
Antigens
Genetic Loci
Risperidone
Antibodies
Genome-Wide Association Study
Patient Selection
Genes
B-Lymphocytes
Biomarkers
Enzyme-Linked Immunosorbent Assay
Control Groups
Peptides
DNA
Brain
anti-IgG
Proteins

Keywords

  • autoantibodies
  • ELISA
  • TRANK1
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Whelan, R., St Clair, D., Mustard, C. J., Hallford, P., & Wei, J. (2018). Study of Novel Autoantibodies in Schizophrenia. Schizophrenia Bulletin, 44(6), 1341-1349. https://doi.org/10.1093/schbul/sbx175

Study of Novel Autoantibodies in Schizophrenia. / Whelan, Ruth; St Clair, David; Mustard, Colette J.; Hallford, Philomena; Wei, Jun (Corresponding Author).

In: Schizophrenia Bulletin, Vol. 44, No. 6, 17.10.2018, p. 1341-1349.

Research output: Contribution to journalArticle

Whelan, R, St Clair, D, Mustard, CJ, Hallford, P & Wei, J 2018, 'Study of Novel Autoantibodies in Schizophrenia' Schizophrenia Bulletin, vol. 44, no. 6, pp. 1341-1349. https://doi.org/10.1093/schbul/sbx175
Whelan, Ruth ; St Clair, David ; Mustard, Colette J. ; Hallford, Philomena ; Wei, Jun. / Study of Novel Autoantibodies in Schizophrenia. In: Schizophrenia Bulletin. 2018 ; Vol. 44, No. 6. pp. 1341-1349.
@article{75cb7f6435f24cf8b03af644a66e46a2,
title = "Study of Novel Autoantibodies in Schizophrenia",
abstract = "A recent genome-wide association (GWA) study confirmed 108 genetic loci that were strongly associated with schizophrenia. Fifteen schizophrenia-associated genes were selected for this study based on a number of selection criteria including their high expression in both brain tissues and B-lymphocyte cells. We aimed to investigate whether individuals with schizophrenia showed different levels of plasma IgG antibodies against protein-derived fragments encoded by these 15 genes. A total of 356 plasma samples were used to analyze circulating IgG antibodies against 18 target peptide antigens using an in-house enzyme-linked immunosorbent assay. Of 18 antigens tested, 6 (derived from DPYD, MAD1L1, ZNF804A, DRD2, TRANK1, and MMP16, respectively) showed increased IgG levels and 3 (derived from TSNARE1, TCF4, and VRK2, respectively) showed decreased IgG levels in patients with schizophrenia compared with control subjects. Receiver operating characteristic (ROC) curve analysis revealed that the anti-TRANK1 IgG assay had the area under the ROC curve of 0.68 (95{\%} CI = 0.62-0.73), with the highest sensitivity of 20.7{\%} against specificity of 95.2{\%} among all 18 tests. There was no difference in positivity of anti-double strand DNA IgG between the patient group and the control group and no correlation between total IgG levels and each individual IgG level tested. Although risperidone treatment showed confounding effects on overall IgG levels in the circulation (combined P = .005), anti-TRANK1 IgG levels did not appear to be significantly affected (t = 1.358, P = .176). In conclusion, this study suggests that circulating anti-TRANK1 IgG is likely to serve as a biomarker for identification of a subgroup of schizophrenia.",
keywords = "autoantibodies, ELISA, TRANK1, schizophrenia",
author = "Ruth Whelan and {St Clair}, David and Mustard, {Colette J.} and Philomena Hallford and Jun Wei",
note = "We thank the patients and healthy volunteers for their support and participation. We also thank NHS Grampian for sample collection as well as Dr Mark Coulson from Inverness College, University of the Highlands and Islands (UHI) and our colleagues at UHI Division of Health Research for their supportive work. This study was supported by the Schizophrenia Association of Great Britain, Bangor, UK. The authors declared that they had no conflict of interests.",
year = "2018",
month = "10",
day = "17",
doi = "10.1093/schbul/sbx175",
language = "English",
volume = "44",
pages = "1341--1349",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Study of Novel Autoantibodies in Schizophrenia

AU - Whelan, Ruth

AU - St Clair, David

AU - Mustard, Colette J.

AU - Hallford, Philomena

AU - Wei, Jun

N1 - We thank the patients and healthy volunteers for their support and participation. We also thank NHS Grampian for sample collection as well as Dr Mark Coulson from Inverness College, University of the Highlands and Islands (UHI) and our colleagues at UHI Division of Health Research for their supportive work. This study was supported by the Schizophrenia Association of Great Britain, Bangor, UK. The authors declared that they had no conflict of interests.

PY - 2018/10/17

Y1 - 2018/10/17

N2 - A recent genome-wide association (GWA) study confirmed 108 genetic loci that were strongly associated with schizophrenia. Fifteen schizophrenia-associated genes were selected for this study based on a number of selection criteria including their high expression in both brain tissues and B-lymphocyte cells. We aimed to investigate whether individuals with schizophrenia showed different levels of plasma IgG antibodies against protein-derived fragments encoded by these 15 genes. A total of 356 plasma samples were used to analyze circulating IgG antibodies against 18 target peptide antigens using an in-house enzyme-linked immunosorbent assay. Of 18 antigens tested, 6 (derived from DPYD, MAD1L1, ZNF804A, DRD2, TRANK1, and MMP16, respectively) showed increased IgG levels and 3 (derived from TSNARE1, TCF4, and VRK2, respectively) showed decreased IgG levels in patients with schizophrenia compared with control subjects. Receiver operating characteristic (ROC) curve analysis revealed that the anti-TRANK1 IgG assay had the area under the ROC curve of 0.68 (95% CI = 0.62-0.73), with the highest sensitivity of 20.7% against specificity of 95.2% among all 18 tests. There was no difference in positivity of anti-double strand DNA IgG between the patient group and the control group and no correlation between total IgG levels and each individual IgG level tested. Although risperidone treatment showed confounding effects on overall IgG levels in the circulation (combined P = .005), anti-TRANK1 IgG levels did not appear to be significantly affected (t = 1.358, P = .176). In conclusion, this study suggests that circulating anti-TRANK1 IgG is likely to serve as a biomarker for identification of a subgroup of schizophrenia.

AB - A recent genome-wide association (GWA) study confirmed 108 genetic loci that were strongly associated with schizophrenia. Fifteen schizophrenia-associated genes were selected for this study based on a number of selection criteria including their high expression in both brain tissues and B-lymphocyte cells. We aimed to investigate whether individuals with schizophrenia showed different levels of plasma IgG antibodies against protein-derived fragments encoded by these 15 genes. A total of 356 plasma samples were used to analyze circulating IgG antibodies against 18 target peptide antigens using an in-house enzyme-linked immunosorbent assay. Of 18 antigens tested, 6 (derived from DPYD, MAD1L1, ZNF804A, DRD2, TRANK1, and MMP16, respectively) showed increased IgG levels and 3 (derived from TSNARE1, TCF4, and VRK2, respectively) showed decreased IgG levels in patients with schizophrenia compared with control subjects. Receiver operating characteristic (ROC) curve analysis revealed that the anti-TRANK1 IgG assay had the area under the ROC curve of 0.68 (95% CI = 0.62-0.73), with the highest sensitivity of 20.7% against specificity of 95.2% among all 18 tests. There was no difference in positivity of anti-double strand DNA IgG between the patient group and the control group and no correlation between total IgG levels and each individual IgG level tested. Although risperidone treatment showed confounding effects on overall IgG levels in the circulation (combined P = .005), anti-TRANK1 IgG levels did not appear to be significantly affected (t = 1.358, P = .176). In conclusion, this study suggests that circulating anti-TRANK1 IgG is likely to serve as a biomarker for identification of a subgroup of schizophrenia.

KW - autoantibodies

KW - ELISA

KW - TRANK1

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85046053527&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbx175

DO - 10.1093/schbul/sbx175

M3 - Article

VL - 44

SP - 1341

EP - 1349

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 6

ER -